Aerie Pharma (AERI) Management NDR Addresses Guidance Revision - Needham

September 19, 2019 7:20 AM EDT Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $54.00 price target on Aerie Pharma (NASDAQ: AERI) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login